BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Davis CL. Interferon and cytotoxic chemotherapy for the treatment of post-transplant lymphoproliferative disorder. Transpl Infect Dis 2001;3:108-18. [PMID: 11395969 DOI: 10.1034/j.1399-3062.2001.003002108.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 Oertel SH, Papp-váry M, Anagnostopoulos I, Hummel MW, Jonas S, Riess HB. Salvage chemotherapy for refractory or relapsed post-transplant lymphoproliferative disorder in patients after solid organ transplantation with a combination of carboplatin and etoposide: Salvage Chemotherapy of PTLD. British Journal of Haematology 2003;123:830-5. [DOI: 10.1046/j.1365-2141.2003.04705.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
2 Nagarsheth NP, Kalir T, Rahaman J. Post-transplant lymphoproliferative disorder of the cervix. Gynecologic Oncology 2005;97:271-5. [DOI: 10.1016/j.ygyno.2004.12.049] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
3 Allen U, Preiksaitis J; AST Infectious Diseases Community of Practice. Epstein-barr virus and posttransplant lymphoproliferative disorder in solid organ transplant recipients. Am J Transplant 2009;9 Suppl 4:S87-96. [PMID: 20070701 DOI: 10.1111/j.1600-6143.2009.02898.x] [Cited by in Crossref: 99] [Cited by in F6Publishing: 66] [Article Influence: 8.3] [Reference Citation Analysis]
4 Burns DM, Crawford DH. Epstein–Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease. Blood Reviews 2004;18:193-209. [DOI: 10.1016/j.blre.2003.12.002] [Cited by in Crossref: 64] [Cited by in F6Publishing: 57] [Article Influence: 3.6] [Reference Citation Analysis]
5 Meerbach A, Gruhn B, Wutzler P. Recent developments in the prevention and treatment of Epstein–Barr virus-associated lymphoproliferative diseases. Expert Opinion on Therapeutic Patents 2005;14:527-47. [DOI: 10.1517/13543776.14.4.527] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
6 Lauro A, Arpinati M, Pinna AD. Managing the challenge of PTLD in liver and bowel transplant recipients. Br J Haematol 2015;169:157-72. [DOI: 10.1111/bjh.13213] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
7 Straathof KC, Savoldo B, Heslop HE, Rooney CM. Immunotherapy for post-transplant lymphoproliferative disease. Br J Haematol 2002;118:728-40. [PMID: 12181039 DOI: 10.1046/j.1365-2141.2002.03594.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 2.1] [Reference Citation Analysis]
8 Lim WH, Russ GR, Coates PT. Review of Epstein–Barr virus and post-transplant lymphoproliferative disorder post-solid organ transplantation (Review Article). Nephrology 2006;11:355-66. [DOI: 10.1111/j.1440-1797.2006.00596.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 45] [Article Influence: 4.1] [Reference Citation Analysis]
9 Larratt L, Hamilton M, Coupland R, Preiksaitis J. Recurrent Epstein-Barr virus associated disease in a cardiac transplant patient: evolution from plasmacytic hyperplasia to diffuse large cell lymphoma: Recurrent EBV in cardiac transplant. Transplant Infectious Disease 2001;3:119-23. [DOI: 10.1034/j.1399-3062.2001.003002119.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
10 Paraskevas S, Coad JE, Gruessner A, Kandaswamy R, Humar A, Sutherland DE, Gruessner RW. Posttransplant Lymphoproliferative Disorder in Pancreas Transplantation: A Single-Center Experience. Transplantation 2005;80:613-22. [DOI: 10.1097/01.tp.0000168366.07896.d7] [Cited by in Crossref: 35] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
11 Straathof KC, Bollard CM, Rooney CM, Heslop HE. Immunotherapy for Epstein‐Barr Virus‐Associated Cancers in Children. The Oncologist 2003;8:83-98. [DOI: 10.1634/theoncologist.8-1-83] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
12 . Epstein-Barr virus and lymphoproliferative disorders after transplantation. American Journal of Transplantation 2004;4:59-65. [DOI: 10.1111/j.1600-6135.2004.00728.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
13 Preiksaitis J. Epstein-Barr virus infection and malignancy in solid organ transplant recipients: strategies for prevention and treatment: Guest editorial. Transplant Infectious Disease 2001;3:56-9. [DOI: 10.1034/j.1399-3062.2001.003002056.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
14 Prockop S, Doubrovina E, Suser S, Heller G, Barker J, Dahi P, Perales MA, Papadopoulos E, Sauter C, Castro-Malaspina H, Boulad F, Curran KJ, Giralt S, Gyurkocza B, Hsu KC, Jakubowski A, Hanash AM, Kernan NA, Kobos R, Koehne G, Landau H, Ponce D, Spitzer B, Young JW, Behr G, Dunphy M, Haque S, Teruya-Feldstein J, Arcila M, Moung C, Hsu S, Hasan A, O'Reilly RJ. Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation. J Clin Invest. 2020;130:733-747. [PMID: 31689242 DOI: 10.1172/jci121127] [Cited by in Crossref: 41] [Cited by in F6Publishing: 28] [Article Influence: 20.5] [Reference Citation Analysis]
15 Leone JP, Christensen K, Bhargava R, Hunter DW, Troppmann C, Lazaron V, Dunn DL, Paraskevas S, Coad JE, Gruessner RWG. Postoperative Management. In: Gruessner RWG, Sutherland DER, editors. Transplantation of the Pancreas. New York: Springer; 2004. pp. 179-266. [DOI: 10.1007/978-1-4757-4371-5_9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
16 Allen UD, Preiksaitis JK; the AST Infectious Diseases Community of Practice. Epstein-Barr Virus and Posttransplant Lymphoproliferative Disorder in Solid Organ Transplantation: EBV and PTLD. American Journal of Transplantation 2013;13:107-20. [DOI: 10.1111/ajt.12104] [Cited by in Crossref: 108] [Cited by in F6Publishing: 78] [Article Influence: 12.0] [Reference Citation Analysis]
17 Segura Huerta A, Gómez Codina J. [Management of lymphoproliferative disorders associated to organ transplantation]. Med Clin (Barc) 2003;120:780-5. [PMID: 12797932 DOI: 10.1016/s0025-7753(03)73844-5] [Reference Citation Analysis]
18 Perrine SP, Hermine O, Small T, Suarez F, O'Reilly R, Boulad F, Fingeroth J, Askin M, Levy A, Mentzer SJ, Di Nicola M, Gianni AM, Klein C, Horwitz S, Faller DV. A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood 2007;109:2571-8. [PMID: 17119113 DOI: 10.1182/blood-2006-01-024703] [Cited by in Crossref: 200] [Cited by in F6Publishing: 165] [Article Influence: 12.5] [Reference Citation Analysis]
19 Allen UD, Preiksaitis JK; AST Infectious Diseases Community of Practice. Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 2019;33:e13652. [PMID: 31230381 DOI: 10.1111/ctr.13652] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 18.3] [Reference Citation Analysis]
20 Parker A, Bowles K, Bradley JA, Emery V, Featherstone C, Gupte G, Marcus R, Parameshwar J, Ramsay A, Newstead C; Haemato-oncology Task Force of the British Committee for Standards in Haematology and British Transplantation Society. Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients - BCSH and BTS Guidelines. Br J Haematol. 2010;149:693-705. [PMID: 20408848 DOI: 10.1111/j.1365-2141.2010.08160.x] [Cited by in Crossref: 143] [Cited by in F6Publishing: 119] [Article Influence: 11.9] [Reference Citation Analysis]
21 Kotton CN, Fishman JA. Viral infection in the renal transplant recipient. J Am Soc Nephrol 2005;16:1758-74. [PMID: 15829710 DOI: 10.1681/ASN.2004121113] [Cited by in Crossref: 144] [Cited by in F6Publishing: 39] [Article Influence: 8.5] [Reference Citation Analysis]
22 Abderrahim E, Harzallah A, Barbouch S, Turki S, Helal I, Ben Abdallah T, Hedri H, Ben Moussa F, Bardi R, Ayed K, Ben Maïz H, Kheder A. [Lymphoproliferative disorders in kidney transplant recipients: incidence, clinical characteristics and outcome]. Rev Med Interne 2008;29:535-40. [PMID: 18262684 DOI: 10.1016/j.revmed.2007.12.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]